Targeting inlammatory macrophages and their products is an efective method for controlling inlammation. he pyrazole analog of curcumin (curcumin pyrazole, PYR) has been reported to possess superior anti-inlammatory activity to curcumin (CUR). However, the role of PYR anti-inlammatory activity in macrophages has not yet been elucidated.
Introduction
Macrophages are key mediators of the pathophysiological component of inlammation. Overproduction of reactive oxygen/nitrogen species and pro-inlammatory cytokines by macrophages recruits additional immune cells that contribute to severe inlammatory reactions and tissue destruction. 1 which is comparable to that of 16 μM of the compounds used in the experimental conditions, and was not toxic to the cells.
Cell Culture
he murine macrophage cell line RAW 264.7 (ATCC, Manassas, VA) was seeded at a density of 3.0 × 10 5 cells/cm 2 in RPMI-1640 (PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% fetal bovine serum (Biochrom GmbH, Berlin, Germany), 1% penicillin/streptomycin (PAA Laboratories GmbH, Pasching, Austria), and 2 mM stable glutamine (Life Technologies, Carlsbad, California). Cells were grown at 37°C in a humidiied 5% CO 2 atmosphere under standard conditions.
Measurement of cytotoxicity
RAW 264.7 macrophages at a density of 3.0 × 10 5 cells/ cm 2 were cultured for 24 h at which time they were treated with CUR and PYR at various concentrations ranging from 0 to 64 μM. DMSO was used as vehicle control. he treated cells were incubated for an additional 24 h and the spent medium was then removed and 200 μl of 0.5 mg/ml of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, MO) solution was added into each well and incubated at 37°C in a CO 2 incubator for 3 h. he resulting formazan crystals were dissolved in DMSO, and the absorbance for each well was detected at 560 nm using a microplate reader. Data were obtained from three independent experiments in triplicate. Cell viability was calculated using the following equation:
[(Abs treated sample / Abs untreated sample ) × 100] Measurement of nitric oxide (NO) production RAW 264.7 macrophages at a density of 3.0 × 10 5 cells/ cm 2 were treated with CUR, PYR, dexamethasone (DEX) or DMSO (vehicle control) in the presence of LPS (5 ng/ml from Escherichia coli serotype O111:B4, Sigma-Aldrich) for 24 h. In another experiment, RAW 264.7 cells were pretreated with 50 μM U0126 (MEK 1/2 inhibitor), 50 μM SB203580 (p38 MAPK inhibitor), and 50 μM SP600125 (JNK inhibitor; all from Sigma-Aldrich) for 30 min. Ater removing the inhibitors, cells were incubated with LPS for 24 h. he conditioned culture media was collected and centrifuged at 1620 × g in a refrigerated centrifuge at 4°C for 10 min. he supernatant was measured for nitrite levels by the Griess assay. 16 Optical density was measured at 548 nm and the nitrite level was determined in μM from a nitrite standard curve (r 2 > 0.990). Data were expressed as the percentage of nitrite levels relative to the nitrite obtained from DMSO control in LPS-treated cells.
Selectivity index
Selectivity index (SI) value was calculated in order to determine the selectivity of CUR and PYR on NO inhibition. SI was obtained by dividing the half maximal cytotoxic concentration (CC 50 ) value for cytotoxicity by the half maximal inhibitory concentration (IC 50 ) value for NO inhibition. 17
Measurement of inlammatory cytokines
RAW 264.7 macrophages at a density of 3.0 × 10 5 cells/ cm 2 were treated with CUR, PYR, or DMSO (vehicle control) Asian Pac J Allergy Immunol DOI 10.12932/AP-130417-0073
Nonsteroidal anti-inlammatory drugs are used extensively in the management of inlammatory conditions; however, their use is associated with drug-related morbidity representing signiicant adverse gastrointestinal, renal, and cardiovascular efects. 2, 3 As such, there is growing interest in the development of more eicient anti-inlammatory drugs derived from natural sources that induce fewer side efects.
Several natural products derived from medicinal plants from hailand display anti-inlammatory properties. 4 Among them, Curcuma longa L. rhizomes have been investigated as a source of compounds with anti-oxidative, anti-cancer, and anti-inlammatory activities in both in vitro and in vivo studies. 5, 6, 7 Curcuminoids are responsible for these activities, the principle compound among them being curcumin (CUR). As such, CUR is a good starting compound for the design of new drugs. Indeed, many stable analogs have been synthesized and investigated. Among these, curcumin pyrazole (PYR), a pyrazole analog, has been found to possess signiicantly enhanced cycloox genase (COX)-2/ COX-1 selectivity and anti-inlammatory activity in a carrageenan-induced paw edema rat model versus CUR. 8 PYR and a prenylated pyrazole analog were found to be potent and selective inhibitors of 5-lipoxygenase, a key enzyme implicated in inlammation-associated induction of cancer. 9 Another CUR-based pyrazole analogue, CNB-001, signiicantly suppressed interleukin (IL)-6, tumor necrosis factor (TNF)-α, and serine peptidase inhibitor, clade E member 1 production both in an inlamed human bronchial epithelial cell model and an in vivo murine model of asthma. 10 Pattern recognition receptors such as toll-like receptors, RIG-I-like receptors, NOD-like receptors, and C-type lectin receptors activate both mitogen-activated protein kinases (MAPKs) and nuclear factor (NF)-κB (NF-κB) pathways, which are responsible for stimulation of inlammatory immune responses in macrophages. 11 As such, MAPKs represent an attractive therapeutic target for the prevention of excessive inlammation and treatment of inlammatory diseases. hree distinct MAPK pathways have been extensively studied, including extracellular signal-regulated kinase (ERK), p38 MAPK, and c-Jun N-terminal kinase (JNK). CUR has been shown to block inducible nitric oxide synthase (iNOS) tyrosine phosphorylation through the inhibition of ERK1/2 12 and suppress pro-inlammatory cytokine production by inhibiting p38 MAPK 13 and JNK in activated RAW 264.7 macrophages. 14 However, whether PYR also acts through inhibition of MAPK is unknown. In the present study, we investigated the anti-inlammatory activities of both CUR and PYR in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages with speciic emphasis on their underlying mechanisms of action against MAPKs.
Methods

Materials
CUR was obtained from C. longa L. rhizomes, and PYR was synthesized as previously described. 15 Both compounds were dissolved in dimethyl sulfoxide (DMSO) and diluted with complete media to obtain inal concentrations of 2-64 μM. DMSO was used as a vehicle control at a concentration of 0.5%, in the presence of LPS (5 ng/ml) for 24 h. Culture media was collected and centrifuged at 1620 × g in a refrigerated centrifuge at 4°C for 10 min and examined for the presence of mouse TNF-α, IL-6 (Millipore, Billerica, MA), and IL-1β (Abcam, Cambridge, United Kingdom) by enzyme-linked immunosorbent assay (ELISA) according to the manufacturers' speciications. Inlammatory cytokine levels were determined against standard curves (r 2 > 0.990).
Western blot analysis
RAW 264.7 macrophages at a density of 3.0 × 10 5 cells/cm 2 were treated with CUR, PYR, or DMSO (vehicle control) for 30 min, followed by LPS (5 ng/ml) treatment for 20 min. Cells were harvested, washed three times with ice-cold phosphate bufered saline and lysed by sonication in sonication bufer containing protease inhibitors. Cell lysates was centrifuged at 4°C for 10 min. Supernatants were removed and protein concentrations were measured by Bradford assay. iNOS, COX-2, phospho-JNK, total JNK, phospho-p38, total p38, phospho-ERK1/2, and total ERK1/2 protein expression in cell lysates were then determined by western blot analysis. Briely, 50 µg protein of each sample was loaded onto 10% sodium dodecyl sulfate-polyacrylamide gel and transferred to polyvinylidene luoride membranes. he membranes were incubated with anti-iNOS (1:1000), anti-COX-2 (1:1000), anti-phospho-JNK (1:500), anti-JNK (1:1000), anti-phospho -p38 (1:500), anti-p38 (1:1000), anti-phospho-ERK1/2 (1:1000), and anti-ERK1/2 (1:1000) antibodies in 5% BSA for overnight at 4°C. All antibodies were purchased from Cell Signaling Technology (Danvers, MA). Membranes were then washed three times with TBST, incubated in anti-rabbit secondary antibody (1:5000) for 1 h at room temperature, washed again and detected with a chemiluminescent system using Hyperilm and ECL plus (GE Healthcare, Buckinghamshire, UK). For the internal loading control, membranes were stripped and reprobed with anti β-actin antibody (1:2000) .
Statistical Analysis
Results are expressed as the mean ± SEM of three independent experiments. he diferences of data were analyzed using ANOVA or independent t-test. Signiicant diference was considered at p < 0.05. Statistical analysis was performed with SPSS (version 17.0).
Results
Efects of CUR and PYR on cytotoxicity and NO production
Treatment of RAW 264.7 macrophages with CUR and PYR (Figure 1A,B) at concentrations up to 8 µM did not afect cell growth or viability (Figure 2A) . However, CUR and PYR were found to have cytotoxic efects with CC 50 values of 27.0 ± 0.54 and 24.0 ± 0.73 µM, respectively (Figure 2C) . PYR concentrations of 2, 4, and 8 µM signiicantly inhibited LPS-induced macrophage secretion of NO in a dose-dependent manner (p < 0.05) (Figure 2B) , with an IC 50 of 3.70 ± 0.16 µM, whereas CUR exhibited an IC 50 of 11.0 ± 0.59 µM (Figure 2C) . As a positive control, DEX inhibited NO secretion with an IC 50 of 5.5 ± 0.33 µM. To assess the selectivity of NO inhibition, SI values were calculated. CUR and PYR exhibited SI values of 2.5 Asian Pac J Allergy Immunol DOI 10.12932/AP-130417-0073 and 6.5, respectively (Figure 2C) . he SI value obtained from PYR represents high selectivity for inhibition of NO secretion rather than general toxicity induction.
Efect of PYR on iNOS and COX-2 protein expression
To evaluate whether the inhibition of NO secretion was associated with the reduction of iNOS expression, western blot analysis of iNOS protein was performed. PYR treatment was found to signiicantly decrease iNOS protein expression in LPS-activated macrophages compared with the DMSO-treated control cells (p < 0.05) (Figure 3A) . We found that PYR, CUR, and DEX all dramatically down-regulated the expression of COX-2, another key inlammatory protein, in LPS-activated macrophages treated with DMSO (p < 0.05) (Figure 3B) . herefore, PYR has the potential to suppress both iNOS and COX-2 protein expression.
Efect of PYR on pro-inlammatory cytokine secretion
To determine whether this inhibition of inlammatory signaling corresponded to reduced pro-inlammatory cytokine secretion, we investigated cytokine secretion in the LPS-activated macrophages by ELISA. PYR dramatically decreased the expression of the pro-inlammatory cytokines TNF-α (Figure 4A) , IL-6 ( Figure 4B) , and IL-1β ( Figure 4C) by 59%, 96%, and 55%, respectively. he anti-inlammatory action of PYR on the inhibition of TNF-α production was greater than that of CUR by 26%. Furthermore, suppression of iNOS/NO and COX-2 was concomitant with the inhibition of pro-inlammatory cytokines by PYR.
Efect of PYR on the MAPKs phosphorylation
To determine whether PYR afected signaling pathways of inlammation, we pretreated macrophages with PYR for 30 min followed by LPS treatment for 20 min and examined the expression and phosphorylation of MAPK proteins by western blot analysis. PYR induced a greater inhibition JNK activation than CUR in LPS-stimulated macrophages (Figure 5A,B) . No further inhibition was observed for phospho-ERK 1/2 and phospho-p38 MAPK. hese results suggest that the JNK signaling pathway is involved in the enhanced activity of PYR in suppression of LPS-induced cytokine secretion in macrophages. To further investigate the role of the MAPK signaling pathway in LPS-induced NO secretion, the speciic MAPK inhibitors MEK inhibitor U0126, p38 MAPK inhibitor SB203580, and JNK inhibitor SP600125 were used. All showed signiicant inhibition of NO secretion in LPS-activated RAW 264.7 macrophages in comparison with LPS alone (Figure 5C) . hese results indicate that MEK/ERK, p38 MAPK, and JNK contribute to LPS-induced NO production and that PYR may have anti-inlammatory beneit.
Discussion
Macrophages are considered key targets for treating inlammatory diseases. In the present study, we found that PYR exhibited more potent anti-inlammatory activity than CUR in LPS-activated RAW 264.7 macrophages, particularly with regard to suppression of NO secretion, iNOS expression, and TNF-α secretion. he underlying mechanism of action is likely due in part to the selective blockade of JNK activation by PYR but not by CUR.
CUR is a potent anti-inlammatory compound isolated from C. longa L. 18 It was shown that curcuminoids at concentrations ranging from 1 to 10 μM are not toxic to RAW 264.7 macrophages. 13, 19 However, CUR was previously found to induce cytotoxicity at higher concentrations (CC 50 = 28.8 ± 0.80 μM). 20 At a concentration of 12 μM, CUR signiicantly inhibits NO production by 50%. 21 CUR potently inhibits NO production with concomitant down-regulation of iNOS mRNA in LPS-activated microglial cells, 22 promotes the ubiquitination and degradation of iNOS, suppresses iNOS activity ater LPS stimulation, 21 and was shown to scavenge NO directly, 23 illustrating the multiple mechanisms through which CUR can inhibit inlammation. CUR also suppresses expression of the inlammatory mediator COX-2 in LPS-activated RAW 264.7 macrophages. 24 In addition, CUR was shown to exert anti-inlammatory activity by binding directly to pro-inlammatory molecules (e.g., TNF-α, COX-1, COX-2, and human α1-acid glycoprotein). 25 Replacement of the β-diketo fragment of CUR by a pyrazole ring signiicantly enhanced its antioxidant and anti-inlammatory activities. 8, 9 A pyrazole derivative of curcumin, CNB-001, was shown to suppress IL-6, TNF-α and GM-CSF production in normal human bronchial epithelial cells and in a murine model of asthma. 10 PYR has been shown to possess more potent activity than CUR in both inhibition of COX-2 in an in vitro, cell-free system and in rats using a carrageenan-induced paw edema assay. 8 We hypothesized that PYR might also be used to inhibit LPS-induced inlammation in human macrophages. In agreement with previous analyses of CUR and PYR, we found PYR to be a superior anti-inlammatory agent.
Previously, the anti-inlammatory efects of CUR were demonstrated to be mediated by the inhibition of MAPK, 13, 26 nuclear factor NF-κB, 24, 26 and signal transducer and activator of transcription 3 (STAT3) with concomitant activation of nuclear factor erythroid 2-related factor-2. 9 MAPK plays a central role in the production of inlammatory mediators such as iNOS, COX-2, and inlammatory cytokines. CUR (10-30 μM) has been shown to inhibit the phosphorylation of ERK, 12 p38, 13 and JNK 14 in activated mouse macrophages, as well as to suppress NF-κB and toll-like receptor 4 signaling in activated macrophages derived from human monocytic THP-1 cells. 26 Rat vascular smooth muscle cells pretreated with the speciic ERK inhibitor PD98059 and p38 MAPK inhibitor SB203580, but not JNK inhibitor SP600125, stimulated with LPS, and treated with CUR exhibited reduced secretion of MCP-1, TNF-α, and NO. 27 Whereas in LPS-activated RAW 264.7 macrophages, each of the MAPK inhibitors U0126, SB203580, and SP600125 were shown to suppress TNF-α and IL-6 secretion and NO production. 28, 29 hus, MAPK signaling pathways act as key mediators of inlammatory response that are targeted by CUR. In this study, our results have demonstrated that PYR exhibited a more potent anti-inlammatory activity than CUR and that this diference likely involves its suppression of JNK activation. Similarly, PYR induced a superior inhibition of the transcriptional activity of STAT3 in comparison to CUR and possessed the inhibition of NF-κB transcriptional activity, which may afect the expression of genes involved in inlammation. 9 hus, PYR not only suppresses JNK activation in activated mouse macrophages but may also inhibit the NF-κB and STAT3 signaling pathways.
he present study showed that structural modiication of CUR with a pyrazole ring to produce PYR, selectively increased NO inhibition and enhanced its anti-inlammatory activity. One possible explanation for this activity is PYR's improved stability in aqueous solutions at physiological pH. 9 CUR was found to be unstable and to rapidly degrade into trans-6-(4'-hydroxy-3'-methoxyphenyl)-2,4-dioxo-5-hexenal. 30 Additionally, PYR retains the hydrogen donor and acceptor properties of the enolized 1,3-dicarbonyl system of CUR, which is critical for the inhibition of inlammatory molecules such as 5-lipoxygenase in human neutrophils. 9 Blockade of this key inlammatory enzyme by PYR may in turn afect other downstream inlammatory molecules, leading to a pronounced attenuation of inlammation.
Conclusion
In summary, we have demonstrated that PYR induces more anti-inlammatory efects and possesses enhanced anti-inlammatory activity over its parent compound, CUR, in macrophages. Taken as a whole, this study demonstrates that PYR potently inhibits JNK activation which is related to its anti-inlammatory activity. Further insights into the mechanisms underlying PYR's anti-inlammatory properties will be pursued in additional models of inlammation to facilitate development of PYR as a potential anti-inlammatory agent.
